TCMs Gain Further U.S. Ground As New Phase III Trial Starts
This article was originally published in PharmAsia News
A Hangzhou-based developer of traditional Chinese medicines (TCMs) has been given the green light by the U.S. Food and Drug Administration to conduct Phase III trials with an injectable TCM-based anticancer drug, which could become the first of its type to enter the U.S. market. The company is also seeking strategic partnerships with big pharmas to advance the trials and for future global development.